跳至主要内容
临床试验/NCT06532240
NCT06532240已完成3 期

Initiation of Methylene Blue for Septic Shock in Adults: A Randomized Clinical Trial

Northern Jiangsu People's Hospital1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2024年8月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
88
试验地点
1
主要终点
Time to shock reversal

研究概览

简要总结

The purpose of this study is to evaluate the efficacy and safety of methylene blue among adult patients with septic shock.

详细描述

Septic Shock is a leading cause of morbidity and mortality in critically ill patients worldwide.

A potential benefit of methylene blue in the treatment of septic shock has recently been described by Estrada. In patients with septic shock, methylene blue initiated within 24 h reduced time to vasopressor discontinuation and increased vasopressor-free days at 28 days. It also reduced length of stay in ICU and hospital without adverse effects.

In this randomized controlled trial, we aim to evaluate the efficacy and safety of methylene blue on septic shock.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age 18 years old or older;
  • diagnosis of septic shock within 12 h.

排除标准

  • recent intake (4-weeks) of selective serotonin re-uptake inhibitors;
  • definitive pulmonary hypertension or chronic pulmonary heart disease;
  • known glucose-6 phosphate dehydrogenase (G-6PD) deficiency;
  • known allergy to methylene blue, phenothiazines, or food dyes;
  • anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician);
  • refusal of the attending staff or patient family;
  • participated in other study.

研究组 & 干预措施

Methylene Blue

Experimental

Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution. Methylene Blue(1 mg/kg/IBW iv over 30min+0.25mg/kg/h x 6h) x 5-days/ discontinution of norepinephrine /ICU discharge (whichever occurred first).

干预措施: Methylene Blue (Drug)

Placebo

Placebo Comparator

5% dextrose solution in a volume to match experimental arm component.

干预措施: Placebo (Drug)

结局指标

主要结局

Time to shock reversal

时间窗: 90 days after randomization

Time to shock reversal was defined as the time from randomization to shock reversal.Reversal of shock was defined as the maintenance of a systolic blood pressure of at least 90 mmHg without vasopressor support for at least 24 h.

次要结局

  • 28-day mortality(28 days after randomization)
  • ICU mortality(90 days after randomization)
  • 90-day mortality(90 days after randomization)
  • Hospital mortality(90 days after randomization)

研究者

发起方
Northern Jiangsu People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Qing-quan Lv

Principal Investigator

Northern Jiangsu People's Hospital

研究点 (1)

Loading locations...

相似试验